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INTRODUCTION
Stress has been implicated as a causative factor in the 
development of depression. It is known that norad-
renergic and serotonergic neurons originating from 
cell bodies in the brain stem ascend to many brain 
regions thought to be involved in some of the symp-
toms associated with depression. Serotonin and nor-
adrenaline are involved in the mechanisms of action 
of most antidepressant drugs and both mediate the 
antidepresant response, their effects being to some 
extent independent. Noradrenergic and serotoner-
gic antidepressants have been associated with some-
what different clinical effects. Noradrenergic anti-
depressants are thought to have prominent effects 
on  motivation  and  drive,  while  antidepressants 
acting on serotonin are believed to have beneficial 
effects on anxiety and mood in depressed patients 
(Montgomery,  1995,  1997).  The  neurochemi-
cal and behavioral effects of reduced central neu-
rotransmitter function and subsequent influence of 
antidepressants are difficult to study in humans for 
ethical reasons. Valuable tools for researching affec-
tive disorders are methods inducing depressive-like 
states in experimental animals. One of the frequent-
ly used approaches is the chronic unpredictable mild 
stress (CUMS) model of depression. Several animal 
models  have  been  developed  to  evaluate  putative 
antidepressants. Among these, the forced swim test 
(FST) proposed by Porsolt and co-workers (1978) 
is a conventional model in which many antidepres-
sants reduce immobility, indicating that this is an 
index of antidepressant activity. However, there are 
few  reports  of  differences  between  noradrenergic 
and serotonergic antidepressants in this test. In a 
number  of  studies,  sertaline  modified  behavioral 
activity in the model (Cervo et al., 1991; Kelly 
and Leonar 1994), while in another study sertra-
line,  fluoxetine,  and  paroxetine  were  all  reported 
to  attenuate  immobility  times  at  moderate  doses 
(Detke  et  al.,  1995).  Weiss  and  co-workers 
(1981) were the first to discriminate different forms 
of active behavior in the FST. They distinguished 
climbing  and  swimming.  It  was  postulated  that 
noradrenergic  reuptake  inhibitors  promote  strug-
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gling  or  climbing  behavior,  and  that  horizontal 
swimming is the behavioral manifestation of selec-
tive treatment with serotonin reuptake inhibitors. A 
number of studies of chronic antidepressant treat-
ment in the FST have been undertaken with vari-
able outcome, e.g., either unchanged or augmented 
behavioral responses relative to the standard acute 
treatment (Borsini, 1995). The effects of antide-
pressants following chronic treatment have received 
little attention. Antidepressants acting on serotonin 
are  thought  to  have  beneficial  effects  on  anxi-
ety in depressed patients (Montgomery, 1995). 
This  view  was  supported  by  the  observation  that 
such antidepressants appear to be effective across 
the spectrum of anxiety disorders, while in some 
anxiety  disorders,  noradrenaline  antidepressants 
were not effective (Dubovsky, 1994). However, 
two studies reported that fluoxetine-treated animals 
displayed  enhanced  anxiety  (Silva  et  al.,  1999; 
Shishkina  et  al.,  2006),  while  Rodgers  and 
co-workers (1997) recorded an anxiolytic-like effect 
with a low dose of maprotiline. 
The purpose of the present study was to examine 
the effects of chronic treatment with maprotiline, a 
selective  inhibitor  of  noradrenaline  reuptake,  and 
fluxilan, a selective inhibitor of serotonin reuptake, 
in  unstressed  controls  and  CUMS  rats,  including 
detailed analyses of behavior to determine if reup-
take inhibitors selective for distinct monoaminer-
gicsystems produce exclusive behavioral responses.
METHODS
Animals
Adult Wistar rat males weighing 280 - 320 g at 
the onset of experiments and maintained in a tem-
perature-controlled room (21±1.0°C) under condi-
tions of a 12 h/12 h light/dark cycle were used.
Drugs and chronic treatment protocols
The  rats  were  randomly  divided  into  control 
(unstressed) and CUMS groups. These two groups 
were further divided into three subgroups each, the 
animals receiving daily injections of: 1. vehicle (ster-
ile water); 2. maprotiline (10 mg/kg); or 3. fluxilan 
(10 mg/kg) via the i.p. route. Exposure to CUMS 
and  the  vehicle,  i.e.,  drug  administration  started 
on the same day and were continued for 4 weeks. 
Maprotiline (Sigma-Aldrich Chemie, Germany) and 
fluxilan  (Aeigis  LTD,  Cyprus)  solutions  in  sterile 
water sonicated for approximately 10 min were pre-
pared ex tempore. 
Chronic unpredictable mild stress (CUMS)
The CUMS procedure, a slight modification of 
the  method  described  by  Grippo  et  al.  (2002), 
was designed to maximize the unpredictable nature 
of the stressors. The CUMS groups were exposed to 
the following stressors in random order: continuous 
illumination (24 h), continuous darkness (24 h), 40º 
cage tilt along the vertical axis, crowding (eight rats 
per cage), soiled cage (300 ml water spilled onto the 
bedding), restraint in a small cage, cold room (4ºC), 
individual housing (24 h), forced running (15 min), 
and food and water deprivation. Animals were also 
maintained under conditions of a reversed light/dark 
cycle from Friday evening to Monday morning. 
Forced swim test procedure
This  test  is  based  on  the  orginal  method  of 
Porsolt  et  al.  (1978).  Rats  were  transferred  to 
individual  cages  24  h  before  the  first  day  of  the 
two-day FST. On the first day of the experiment, 
the rats were plunged individually into a glass cyl-
inder (height, diameter: 35x24 cm) containing 20 
cm of water at 25 0C. Clean water was used for each 
behavioral  trial,  as  use  of  water  previously  swum 
in by another rat has been shown to alter behavior. 
The animals were left to swim in the water for 15 
min before being removed, dried with paper towels, 
and returned to their home cage. Twenty-four hours 
later  the  procedure  was  repeated  in  a  5-min  test 
session. The total times spent in each of the three 
behavioral classifications during the 5-min test ses-
sion were recorded. Instead of measuring the dura-
tion of the presence or absence of only immobility, 
the sampling procedure measures the frequency of 
behaviors over 5-s intervals during the test session. 
The  behaviors  measured  were:  immobility  (i.e., 
floating and only making the movements necessary 
to keep the head above water); swimming (i.e., mak-
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inder across the top of the water); and climbing (i.e., 
making intense movements with all four limbs, with 
the two forepaws either breaking the surface of the 
water or directed against the walls of the cylinder). 
Uncontrollable  reflex  movements  during  periods 
of immobility, such as shivering or wiping of water 
away from the eyes, were ignored. 
Elevated plus-maze procedure
The plus-maze consisted of two open arms, 50 
x 10 cm (length x width), and two enclosed arms, 
50 x 10 x 50 cm (length x width x height), arranged 
so that the two arms of each type were opposite to 
each other. The maze was elevated to a height of 50 
cm. The rats were placed individually in the center 
of the maze facing a closed arm and allowed 5 min 
of  free  exploration.  The  behavior  of  each  animal 
in the maze was analyzed, taking into account the 
standard measures recorded in each section of the 
maze  (closed  and  open  arms,  central  platform), 
comprising the percent of open arm entries (arm 
entry defined as all four paws into an arm), total arm 
entries, and the percent of time spent by the animals 
in open arms of the maze. 
Statistics
Statistical analyses included the one-way ANOVA 
test. Data expressed as means ± SEM represent an 
average of eight animals. Statistical significance was 
accepted at p < 0.05.
RESULTS
The  results  presented  in  Table  1  show  that 
vehicle-treated  CUMS  rats  were  characterized  by 
significantly  decreased  climbing  and  swimming 
and increased immobility in comparison with the 
vehicle-treated unstressed control. There were sig-
nificant effects of treatment with both antidepres-
sants  maprotiline  (p<0.001)  and  fluxilan  (p<0.01) 
-  on  immobility  time.  Both  selective  reuptake  of 
inhibitors  resulted  in  a  significant  reduction  in 
time spent immobile in comparison with vehicle-
treated unstressed control and CUMS rats. Climbing 
was  significantly  increased  in  maprotiline-treated 
unstressed control and CUMS rats compared with 
the vehicle-treated groups. Administration of fluxi-
lan in the unstressed control and CUMS variants 
had no significant effect on climbing compared to 
the  vehicle-treated  groups.  Swimming  as  a  form 
of  active  behavior  was  exclusively  elicited  by  the 
serotonin reuptake inhibitor fluxilan; as a result, the 
maprotiline-treated groups were identical to those 
of the vehicle-administered controls.
CUMS rats treated with the vehicle showed sig-
nificant (p<0.01) decrease of total arm entries, per-
centage of entries into open arms and time spent in 
open arms compared to vehicle-treated unstressed 
control rats. Maprotiline significantly increased the 
percentage of open arm entries in unstressed control 
(p<0.05)  and  CUMS  (p<0.01)  rats  and  increased 
the percentage of time spent in open arms in the 
unstressed control (p<0.001) and CUMS (p<0.05) 
variants. Animals treated with fluxilan in both the 
unstressed  control  and  CUMS  variants  also  dis-
played increase in each of the two parameters, but it 
was not statistically significant (Table 2).
DISCUSSION
Chronic stress has been found to affect different 
behavioral variables. We found that long-term social 
isolation  in  rats  produces  anxiety  (Spasojevic 
et  al.,  2007).  Chronic  unpredictable  mild  stress, 
which  has  been  used  as  a  model  of  depression, 
was found to evoke various behavioral alterations, 
including  increased  immobility,  decreased  climb-
ing  and  swimming,  and  changes  in  anxiety-like 
behavior. In the present study, analysis of immobility 
revealed reductions caused by both selective reup-
take  inhibitors,  maprotiline  and  fluxilan,  follow-
ing chronic treatment. Consistent with the present 
findings, Connor and co-workers (2000) did not 
find any changes in immobility after treatment with 
the serotonergic reuptake inhibitor paroxetine, but 
they observed that noradrenergic reuptake inhibitor 
desipramine  significantly  decreased  immobility  in 
the FST. Contradictory results can be attributed to 
different procedural approaches used in individual 
experiments. This is probably important in defining 
the role of brain monoamine neurotransmitters in 
depression. The results of Cryan and co-workers 
(2002) suggest that serotonin and noradrenaline are 
not ordinarily involved in mediating baseline stress-N. SPASOJEVIĆ ET AL. 36
plus-maze test
Variable Total arm entries Percent open arm entries Percent open arm time
Unstressed control
+
vehicle
6,50 ± 0,76 18,67 ± 2,49 6,33 ± 1,05
CUMS
+
vehicle
##
2,00 ± 0,52
##
5,50 ± 1,18
##
1,16 ± 0,20
Unstressed control
+
maprotiline
7,50 ± 0,76
 *
30,83 ± 4,65
 ***
35,83 ± 4,41
CUMS
+
maprotiline 2,67 ± 0,42
**
17,16 ± 2,15
*
4,52 ± 1,08
Unstressed control
+
fluxilan 3,83 ± 0,60 24,50 ± 2,32 7,76 ± 0,99
CUMS
+
fluxilan
4,33 ± 0,49 7,67 ± 0,88 2,80 ± 0,66
Table. 1. Effect of chronic maprotiline and fluxilan treatment on immobility, climbing, and swimming behaviour sampled every 5 
sec during the 5-min FST. Data expressed as means ± SEM of nine rats. Statistical significance: # p<0.05; ### p<0.001 unstressed 
vehicle-receiving control vs. CUMS group receiving vehicle; ** p<0.01; *** p<0.001 maprotiline vs. vehicle; + p<0.05; ++ p<0.01; +++ 
p<0.001 fluxilan vs. vehicle.
Table. 2. Effect of chronic maprotiline and fluxilan treatment on total arm entries, the percentage of entries into open arms, and 
percentage of time spent in open arms of the elevated plus-maze. Data expressed as means ± SEM of nine rats. Statistical significance: 
## p<0.01 unstressed vehicle-receiving control vs. CUMS group receiving vehicle; * p<0.05; ** p<0.01; *** p<0.001 maprotiline vs. 
vehicle.
FST
Variable climbing immobility  swimming
Unstressed control
+
vehicle
15,28 ± 1,30 20,87 ± 1,20 23,86 ± 1,60
CUMS
+
vehicle
 ###
8,17 ± 0,48
###
32,83 ± 2,85
 #
19,00 ± 1,10
Unstressed control
+
maprotiline
***
35,17 ± 1,72
 ***
5,00 ± 1,79 19,83 ± 2,43
CUMS
+
maprotiline
***
21,50 ± 0,85
 ***
26,00 ± 0,86
**
12,67 ± 1,17
Unstressed control
+
fluxilan 10,60 ± 0,87
++
15,60 ± 0,51
+++
33,80 ± 0,73
CUMS
+
fluxilan
8,25 ± 0,75 +++
20,25 ± 0,85
 +
31,50 ± 3,77BEHAVIORAL EFFECTS OF MAPROTILINE AND FLUxILAN IN RATS 37
evoked performance, but do mediate changes in per-
formance  produced  by  antidepressant  treatments. 
The  given  neurotransmitters  could  be  involved 
in  augmenting  immobility  caused  by  stress,  but 
this hypothesis has not been tested. Espejo and 
Minano  (1999)  suggested  dopaminergic  media-
tion of the FST. They showed that prefronticortical 
dopamine lesions reduce overall immobility scores. 
The  sequence  of  behaviors  in  the  FST  may  be 
important for understanding the different functions 
of climbing and swimming. Climbing is ordinarily 
observed during the first minutes of the 5-min test, 
bouts  of  swimming  occur  throughout  the  inter-
val, and immobility is most frequent at the end of 
interval. Climbing and swimming appear to be two 
separate  responses,  linked  sequentially  in  series, 
that facilitate escape during the FST. Reneric and 
Lucki  (1998)  as  well  as  Cryan  and  co-work-
ers  (2005)  reported  that  climbing  and  swimming 
are  exclusively  evoked  by  selective  noradrenergic 
and  serotonergic  reuptake  inhibitors,  respectively. 
In  the  present  study,  enhancement  of  climbing 
behavior  appeared  to  be  exclusively  a  product  of 
noradrenergic reuptake inhibition, while augmen-
tation  of  swimming  was  exclusively  the  product 
of serotonergic reuptake inhibition. Because three 
serotonergic  reuptake  inhibitors  -  fluoxetine,  ser-
traline, and paroxetine similarly evoked increased 
swimming  in  the  FST,  a  serotonergic  mechanism 
was  inferred  to  mediate  their  behavioral  activity 
(Cryan et al., 2005). Subsequently, it was shown 
that the swimming behavior produced by fluoxetine 
was prevented by pretreatment with the tryptophan 
hydroxylase inhibitor parachlorophenylalanine, but 
not  the  climbing  behavior  produced  by  the  nor-
adrenaline  reuptake  inhibitor  desipramine  (Page 
et al., 1999). 
The obtained results suggest that central norad-
renergic and serotonergic systems might be affected 
differently during the FST. Izumi and co-wokers 
(1996) reported that stress induced by either han-
dling or saline injection increased the tissue content 
of noradrenaline as well as immobility in the tail 
suspension test in rats, whereas the tissue content of 
serotonin was not affected.
The elevated plus-maze is one of the most widely 
used  animals  models  in  contemporary  preclinical 
research  on  anxiety  (Handley  and  McBlane, 
1993;  Hog,  1996;  Rodgers  and  Cole,  1994). 
This model is based on the innate fear rodents have 
for open and elevated spaces. Stressed animals spent 
less  time  in  open  arms  and  more  time  in  closed 
arms (Qi et al., 2006). Evidence derived from clini-
cal  studies  suggests  that  antidepressant  drugs  can 
effectively treat anxiety disorders. Recent research 
has suggested that noradrenergic and serotoniner-
gic reuptake inhibitors are effective in this regard 
(Nowakowska et al., 2000; Kurt et al., 2000). 
However, preclinical investigations with serotoner-
gic reuptake inhibitors in animal models of anxiety 
disorders  reveal  highly  variable  effects  of  these 
drugs (Silva et al., 1999). Our results show that 
chronic  treatment  with  maprotiline  increased  the 
percentage of open arm entries and time spent in 
open arms, suggesting an anxiolytic effect. Chronic 
treatment with fluxilan did not change the percent-
age of open arm entries or time spent in open arms, 
suggesting an anxiogenic profile. These results could 
be connected with the data of Shishkina and co-
workers (2006), who found that animals chronically 
treated with fluoxetine displayed enhanced anxiety 
and decreased locomotor activity. These differences 
observed  for  the  effects  of  fluxilan  in  relation  to 
those  reported  for  maprotiline  and  probably  due 
to the different distinct pharmacological profiles of 
these drugs. 
In  conclusion,  our  results  indicate  that  the 
anxiogenic effects of chronic fluxilan treatment are 
similar to those reported in many other studies. The 
lack of anxiolytic effects of chronic fluxilan treat-
ment also conforms with the poor efficacy of this 
drug in generalized anxiety disorders.
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РАЗЛИЧИТО ДЕЈСТВО МАПРОТИЛИНА И ФЛУКСИЛАНА НА ПОНАШАЊЕ ПАЦОВА
НАТАША СПАСОЈЕВИЋ, ЉУБИЦА ГАВРИЛОВИЋ и СЛАЂАНА ДРОЊАК
Лабораторија за молекуларну биологију и ендокринологију, Институт за нуклеарне науке "Винча", 
11001 Београд, Србија
Серотонин  и  норадреналин  су  укључени  у 
механизам дејства већине антидепресива. Изуча-
вано је дејство хроничног третмана са мапроти-
лином, који је селективни инхибитор поновног 
преузимања норадреналина и флуксилана, селек-
тивног инхибитора поновног преузимања серото-
нина, на понашање код нестресираних контрола 
и пацова изложених хроничном непредвидивом 
благом  стресу  (CUMS),  тестом  пливања  (FST) 
и тестом плус лавиринт платформе. Оба селек-
тивна инхибитора доводе до значајног смањења 
имобилности. Мапротилин доводи до повећаног 
пењања, док флуксилан изазива повећано плива-
ње,како код нестресираних контрола тако и код 
CUMS пацова током теста пливања. Животиње 
третиране  са  мапротилином  показују  смањење 
анксиозности, док пацови третирани са флукси-
ланом показују повећање анксиозности. Добије-
ни реултати указују да тест пливања може утица-
ти различито на централни норадренергички и 
серотонергички систем. Резултати такође показу-
ју да је анксиогено дејство хроничног третмана 
са флуксиланом слично са резултатима других 
студија. Уочене разлике између мапротилина и 
флуксилана  су  вероватно  резултат  различитог 
фармаколошког профила ова два лека.